CF
DMAC icon

Cantor Fitzgerald’s DiaMedica Therapeutics DMAC Stock Holding History

Cantor Fitzgerald’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$687K – 258
2025
Q3 		$687K Buy
+100,000
New +$542K 0.01% 260
2022
Q3 		– Sell
-14,691
Closed -$30K – 804
2022
Q2 		$30K Buy
+14,691
New +$34.3K ﹤0.01% 734

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Cantor Fitzgerald's DMAC Position: Q4 2025 in Review

Cantor Fitzgerald sold out of DiaMedica Therapeutics (DMAC) in Q4 2025, closing a stake of 100,000 shares — an estimated $687K sold.

Cantor Fitzgerald first reported a position in DMAC in Q2 2022 and held it in 2 quarters. The position peaked at $687K in Q3 2025. 92 funds tracked by Wall St. Rank hold DMAC as of Q4 2025.

  • Cantor Fitzgerald reported no remaining DiaMedica Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 100,000 DiaMedica Therapeutics shares in Q4 2025, an estimated $687K.
  • Cantor Fitzgerald first reported a position in DiaMedica Therapeutics in Q2 2022 and held it in 2 quarters.
  • Cantor Fitzgerald's DiaMedica Therapeutics position peaked at $687K in Q3 2025.
  • 92 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.